Patents by Inventor Christina Esdar

Christina Esdar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200354382
    Abstract: ?-amino boronic acid derivatives are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer.
    Type: Application
    Filed: August 21, 2018
    Publication date: November 12, 2020
    Applicant: Merck Patent GmbH
    Inventors: Markus Klein, Oliver Schadt, Christina Esdar
  • Publication number: 20200190054
    Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
    Type: Application
    Filed: February 20, 2020
    Publication date: June 18, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Dieter DORSCH, Mathilde MUZERELLE, Lars BURGDORF, Margarita WUCHERER-PLIETKER, Paul CZODROWSKI, Christina ESDAR, Christos TSAKLAKIDIS
  • Publication number: 20200190055
    Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
    Type: Application
    Filed: February 20, 2020
    Publication date: June 18, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Dieter DORSCH, Mathilde MUZERELLE, Lars BURGDORF, Margarita WUCHERER-PLIETKER, Paul CZODROWSKI, Christina ESDAR, Christos TSAKLAKIDIS
  • Patent number: 10669251
    Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 2, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Mathilde Muzerelle, Lars Burgdorf, Margarita Wucherer-Plietker, Paul Czodrowski, Christina Esdar, Christos Tsaklakidis
  • Publication number: 20190367620
    Abstract: The present invention relates to antibodies with specificity for FGFR1. More particularly, the invention relates to monoclonal antibodies that bind specifically to and neutralize human, macaque and mouse forms of FGFR1 with high affinity. The invention also relates to nucleic acids encoding said antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis and/or treatment of cancers.
    Type: Application
    Filed: November 21, 2017
    Publication date: December 5, 2019
    Inventors: CHRISTEL IFFLAND, CHRISTINA ESDAR, XINYAN ZHAO, QI AN, JOHANNES YEH, GANG HAO, LARS TOLEIKIS, VANITA SOOD, DAVID NANNEMANN, ROBIN LYTLE, BJOERN HOCK
  • Publication number: 20190023685
    Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
    Type: Application
    Filed: December 16, 2016
    Publication date: January 24, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Dieter DORSCH, Mathilde MUZERELLE, Lars BURGDORF, Margarita WUCHERER-PLIETKER, Paul CZODROWSKI, Christina ESDAR, Christos TSAKLAKIDIS
  • Patent number: 9751842
    Abstract: Compounds of the formula I in which R1, X and n have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: September 5, 2017
    Assignee: Marck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Dieter Dorsch, Christina Esdar, Birgitta Leuthner
  • Patent number: 9493444
    Abstract: The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: November 15, 2016
    Assignees: Merck Patent GmbH, Cancer Research Technology Limited
    Inventors: Kai Schiemann, Frank Stieber, Christina Esdar
  • Publication number: 20160318876
    Abstract: Compounds of the formula I in which R1, X and n have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Application
    Filed: May 30, 2014
    Publication date: November 3, 2016
    Applicant: Marck Patent GmbH
    Inventors: Hans-Peter BUCHSTALLER, Dieter DORSCH, Christina ESDAR, Birgitta LEUTHNER
  • Patent number: 9481668
    Abstract: The compound N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-5-ethyl-1 -(pyrimidin-5-yl)-1H-pyrazole-4-carboxamide and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, is an inhibitor of RON and can be employed, for the treatment of cancer.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: November 1, 2016
    Assignee: Merck Patent GmbH
    Inventors: Oliver Schadt, Christina Esdar, Carsten Schultz-Fademrecht, Jan Eickhoff
  • Patent number: 9339503
    Abstract: Compounds of the formula I in which U, V and W have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: May 17, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Hans-Peter Buchstaller, Christina Esdar, Birgitta Leuthner
  • Publication number: 20160115154
    Abstract: The compound N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-5-ethyl-1-(pyrimidin-5-yl)-1H-pyrazole-4-carboxamide and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, is an inhibitor of RON and can be employed, for the treatment of cancer.
    Type: Application
    Filed: May 7, 2014
    Publication date: April 28, 2016
    Applicant: Merck Patent GmbH
    Inventors: Oliver SCHADT, Christina ESDAR, Carsten SCHULTZ-FADEMRECHT, Jan EICKHOFF
  • Patent number: 9249140
    Abstract: Compounds of the formula I, in which X1, X2, X3, X4, X5, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Claim 1, are kinase inhibitors and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: February 2, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Timo Heinrich, Felix Rohdich, Christina Esdar, Mireille Krier, Hartmut Greiner
  • Publication number: 20150218155
    Abstract: Compounds of the formula I, in which X1, X2, X3, X4, X5, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Claim 1, are kinase inhibitors and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: July 26, 2012
    Publication date: August 6, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Timo Heinrich, Felix Rohdich, Christina Esdar, Mireille Krier, Hartmut Greiner
  • Patent number: 8999986
    Abstract: Pyrrolo[2,3-d]pyrazin-7-ylpyrimidine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumors.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: April 7, 2015
    Assignee: Merck Patent GmbH
    Inventors: Margarita Wucherer-Plietker, Christina Esdar
  • Publication number: 20150025071
    Abstract: Compounds of the formula I in which U, V and W have the meanings indicated in claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Application
    Filed: January 14, 2013
    Publication date: January 22, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Hans-Peter Buchstaller, Christina Esdar, Birgitta Leuthner
  • Publication number: 20150005294
    Abstract: The invention provides novel substituted azaheterocyclic compounds compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.
    Type: Application
    Filed: January 10, 2013
    Publication date: January 1, 2015
    Applicants: CANCER RESEARCH TECHNOLOGY LIMITED, MERCK PATENT GMBH
    Inventors: Kai Schiemann, Frank Stieber, Christina Esdar
  • Patent number: 8906916
    Abstract: Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in Claim 1, are kinase inhibitors and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: December 9, 2014
    Assignee: Merck Patent GmbH
    Inventors: Timo Heinrich, Christina Esdar, Hartmut Greiner
  • Patent number: 8895559
    Abstract: A variety of specific compounds within the scope of formula I which are useful as PI3K inhibitors and can be employed for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumours, and pharmaceutical compositions and kits containing said specific compounds.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: November 25, 2014
    Assignee: Merck Patent GmbH
    Inventors: Markus Klein, Ulrich Emde, Hans-Peter Buchstaller, Christina Esdar, Oliver Poeschke
  • Patent number: 8802866
    Abstract: Compounds of the formula (I), in which X1, X2, L, Y, R2, R3, R4, R5, R6, R7, R8, R9, R10 have the meanings indicated in claim 1, are PI3K inhibitors and can be employed, inter alia, for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumors.
    Type: Grant
    Filed: September 6, 2010
    Date of Patent: August 12, 2014
    Assignee: Merck Patent GmbH
    Inventors: Ulrich Emde, Hans Peter Buchstaller, Markus Klein, Christina Esdar, Joerg Bomke